Prospective, Randomized, Single-blind, Active-controlled (Part B), Multi-center Phase II Clinical Trial to Explore the Fixed Starting Dose and Treatment Schedule and to Evaluate the Safety of GX-E2 Administered Intravenously/Subcutaneously in the Anemic Patients Diagnosed with Chronic Kidney Disease Receiving Hemodialysis (HD)/Peritoneal dialysis (PD)
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs GX E2 (Primary) ; GX E2 (Primary) ; Darbepoetin alfa; Darbepoetin alfa
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Genexine
- 13 Oct 2017 Status changed from active, no longer recruiting to completed.
- 25 Apr 2017 Planned number of patients changed from 250 to 252.
- 25 Apr 2017 Planned End Date changed from 1 Jan 2016 to 1 Apr 2016.